Year archive

Oramed Pharmaceuticals Inc. — 2021 filings

All 172 regulatory filings released by Oramed Pharmaceuticals Inc. (ORMP) in 2021, sourced directly from the official regulator.

172 Filings

2021 Period

2021 filings (172)

Filing	Released	Lang
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-RABINOWITZ MICHAEL Director's Dealing	2021-12-31	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-RABINOWITZ MICHAEL Director's Dealing	2021-12-31	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-KIDRON NADAV Director's Dealing	2021-12-31	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-KIDRON NADAV Director's Dealing	2021-12-31	English
Director's Dealing 2021 Director's Dealing	2021-12-30	English
Director's Dealing 2021 Director's Dealing	2021-12-30	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP -RAKIN KEVIN Director's Dealing	2021-12-18	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP -RAKIN KEVIN Director's Dealing	2021-12-18	English
Director's Dealing 2021 Director's Dealing	2021-12-17	English
8K: appointed Netanel Derovan to serve as Chief Legal Officer, effective January 9, 2022. Board/Management Information	2021-12-08	English
8K: appointed Netanel Derovan to serve as Chief Legal Officer, effective January 9, 2022. Regulatory Filings	2021-12-08	English
CURRENT REPORT Regulatory Filings	2021-12-08	English
Investor Presentation-Devember 2021 Investor Presentation	2021-12-08	English
Investor Presentation-Devember 2021 Regulatory Filings	2021-12-08	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-12-08	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-12-08	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-12-08	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Report Publication Announcement	2021-12-08	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-12-08	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-12-08	English
CURRENT REPORT Regulatory Filings	2021-12-07	English
OWNERSHIP DOCUMENT Director's Dealing	2021-12-07	English
Director's Dealing 2021 Director's Dealing	2021-12-07	English
Director's Dealing 2021 Director's Dealing	2021-12-07	English
ORM 10-K For the Fiscal Year Ended August 31, 2021 Annual Report FY 2021	2021-11-25	English
ORM 10-K For the Fiscal Year Ended August 31, 2021 Report Publication Announcement FY 2021	2021-11-25	English
ANNUAL REPORT Annual Report FY 2021	2021-11-24	English
Form 424b5- PROSPECTUS SUPPLEMENT (to prospectus dated July 26, 2021) Capital/Financing Update	2021-11-05	English
Form 424b5- PROSPECTUS SUPPLEMENT (to prospectus dated July 26, 2021) Regulatory Filings	2021-11-05	English
FORM 8-K, Registration Direct Offering of 2,000,000 shares for an offering price of $25 per Share Regulatory Filings	2021-11-05	English
FORM 8-K, Registration Direct Offering of 2,000,000 shares for an offering price of $25 per Share Report Publication Announcement	2021-11-05	English
PROSPECTUS SUPPLEMENT Prospectus	2021-11-04	English
CURRENT REPORT Regulatory Filings	2021-11-04	English
Oravax Medical Inc( subsidiary) has received clearance from the South African Health Products Regulatory Authority to commence patient enrollment in a first in human, Phase 1 clinical trial, for its o Regulatory Filings	2021-10-29	English
Oravax Medical Inc( subsidiary) has received clearance from the South African Health Products Regulatory Authority to commence patient enrollment in a first in human, Phase 1 clinical trial, for its o Regulatory Filings	2021-10-29	English
CURRENT REPORT Regulatory Filings	2021-10-29	English
FORM 5- ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-10-16	English
FORM 5- ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Regulatory Filings	2021-10-16	English
OWNERSHIP DOCUMENT Director's Dealing	2021-10-15	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-RAKIN KEVIN Director's Dealing	2021-09-21	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-RAKIN KEVIN Director's Dealing	2021-09-21	English
Director's Dealing 2021 Director's Dealing	2021-09-20	English
Form SC13D/A-Nadav Kidron Major Shareholding Notification	2021-09-03	English
Form SC13D/A-Nadav Kidron Major Shareholding Notification	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Major Shareholding Notification	2021-09-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-09-03	English
AMENDMENT NO. 5 TO SCHEDULE 13D Major Shareholding Notification	2021-09-02	English
OWNERSHIP DOCUMENT Director's Dealing	2021-09-02	English
Director's Dealing 2021 Director's Dealing	2021-09-02	English
Director's Dealing 2021 Director's Dealing	2021-09-02	English
Director's Dealing 2021 Director's Dealing	2021-09-02	English
Director's Dealing 2021 Director's Dealing	2021-09-02	English
entered into an equity distribution agreement with Canaccord Genuity LLC, as agent;Termination of Equity Distribution Agreement dated July 15, 2021 Regulatory Filings	2021-09-01	English
entered into an equity distribution agreement with Canaccord Genuity LLC, as agent;Termination of Equity Distribution Agreement dated July 15, 2021 Regulatory Filings	2021-09-01	English
PROSPECTUS SUPPLEMENT dated July 26, 2021 Capital/Financing Update	2021-09-01	English
PROSPECTUS SUPPLEMENT dated July 26, 2021 Regulatory Filings	2021-09-01	English
CURRENT REPORT Regulatory Filings	2021-09-01	English
PROSPECTUS SUPPLEMENT Prospectus	2021-09-01	English
8K-results of 2021 Annual Meeting of Shareholders AGM Information	2021-09-01	English
8K-results of 2021 Annual Meeting of Shareholders Regulatory Filings	2021-09-01	English
CURRENT REPORT Regulatory Filings	2021-08-31	English
prospectus supplement date August 13, 2021 Share Issue/Capital Change	2021-08-14	English
prospectus supplement date August 13, 2021 Capital/Financing Update	2021-08-14	English
424B7 Prospectus	2021-08-13	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-08-12	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-08-12	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-08-12	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-08-12	English
OWNERSHIP DOCUMENT Director's Dealing	2021-08-11	English
OWNERSHIP DOCUMENT Director's Dealing	2021-08-11	English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- FORM 4 Director's Dealing	2021-08-07	English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- FORM 4 Director's Dealing	2021-08-07	English
Director's Dealing 2021 Director's Dealing	2021-08-06	English
Investor Presentation - August 2021 Regulatory Filings	2021-08-05	English
Investor Presentation - August 2021 Report Publication Announcement	2021-08-05	English
CURRENT REPORT Regulatory Filings	2021-08-05	English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Major Shareholding Notification	2021-08-05	English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Director's Dealing	2021-08-05	English
Director's Dealing 2021 Director's Dealing	2021-08-04	English
FORM 8-K- Oramed appointed Michael Rabinowitz to serve as Chief Commercial Officer Board/Management Information	2021-08-03	English
FORM 8-K- Oramed appointed Michael Rabinowitz to serve as Chief Commercial Officer Regulatory Filings	2021-08-03	English
CURRENT REPORT Regulatory Filings	2021-08-02	English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 30, 2021 Proxy Solicitation & Information Statement	2021-07-29	English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 30, 2021 Remuneration Information	2021-07-29	English
DEFINITIVE PROXY STATEMENT Proxy Solicitation & Information Statement	2021-07-28	English
Regulatory Filings 2021 Regulatory Filings	2021-07-27	English
Regulatory Filings 2021 Regulatory Filings	2021-07-22	English
Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial Regulatory Filings	2021-07-21	English
Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial Report Publication Announcement	2021-07-21	English
Regulatory Filings 2021 Regulatory Filings	2021-07-21	English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 30, 2021 Proxy Solicitation & Information Statement	2021-07-18	English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 30, 2021 Proxy Solicitation & Information Statement	2021-07-18	English
PRELIMINARY PROXY STATEMENT Regulatory Filings	2021-07-16	English
FORM S-3-REGISTRATION STATEMENT Capital/Financing Update	2021-07-16	English
FORM S-3-REGISTRATION STATEMENT Report Publication Announcement	2021-07-16	English
entered into an equity distribution agreement with Canaccord Genuity LLC, as agent; Amendments to Articles of Incorporation Regulatory Filings	2021-07-16	English
entered into an equity distribution agreement with Canaccord Genuity LLC, as agent; Amendments to Articles of Incorporation Report Publication Announcement	2021-07-16	English
REGISTRATION STATEMENT Registration Form	2021-07-15	English
CURRENT REPORT Regulatory Filings	2021-07-15	English
FORM 10-Q - QUARTERLY REPORT For the quarterly period ended May 31, 2021 Interim / Quarterly Report 9M 2021	2021-07-15	English
FORM 10-Q - QUARTERLY REPORT For the quarterly period ended May 31, 2021 Report Publication Announcement Q2 2021	2021-07-15	English
QUARTERLY REPORT Interim / Quarterly Report Q3 2021	2021-07-14	English
FORM 3- STATEMENT OF BENEFICIAL OWNERSHIP SECURITIES-Silberman David Director's Dealing	2021-07-09	English
FORM 3- STATEMENT OF BENEFICIAL OWNERSHIP SECURITIES-Silberman David Director's Dealing	2021-07-09	English
OWNERSHIP DOCUMENT Director's Dealing	2021-07-08	English
Oramed Pharmaceuticals to Join Russell 2000 and Russell 3000 Indexes Regulatory Filings	2021-06-22	English
Oramed Pharmaceuticals to Join Russell 2000 and Russell 3000 Indexes Report Publication Announcement	2021-06-22	English
PROSPECTUS SUPPLEMENT Capital/Financing Update	2021-06-17	English
PROSPECTUS SUPPLEMENT Regulatory Filings	2021-06-17	English
entered into an equity distribution agreement with Canaccord Genuity LLC, as agent, pursuant to which the Company may issue and sell shares of its common stock up to $28,000,000 Regulatory Filings	2021-06-17	English
entered into an equity distribution agreement with Canaccord Genuity LLC, as agent, pursuant to which the Company may issue and sell shares of its common stock up to $28,000,000 Regulatory Filings	2021-06-17	English
FORM 462(B) REGISTRATION STATEMENT Capital/Financing Update	2021-06-16	English
FORM 462(B) REGISTRATION STATEMENT Regulatory Filings	2021-06-16	English
CURRENT REPORT Regulatory Filings	2021-06-16	English
PROSPECTUS SUPPLEMENT Prospectus	2021-06-16	English
REGISTRATION STATEMENT Regulatory Filings	2021-06-16	English
FORM 8-K- Oramed appointed David Silberman to serve as Chief Financial Officer Board/Management Information	2021-05-26	English
FORM 8-K- Oramed appointed David Silberman to serve as Chief Financial Officer Regulatory Filings	2021-05-26	English
CURRENT REPORT Regulatory Filings	2021-05-25	English
Letter to Shareholders with Updates on Oral Insulin & COVID-19 Vaccine Legal Proceedings Report	2021-05-25	English
Letter to Shareholders with Updates on Oral Insulin & COVID-19 Vaccine Report Publication Announcement	2021-05-25	English
8K-The CFO resigned from his positions with the Company Board/Management Information	2021-05-11	English
8K-The CFO resigned from his positions with the Company Report Publication Announcement	2021-05-11	English
REPORT OF FOREIGN PRIVATE ISSUER Regulatory Filings	2021-05-10	English
FORM 10Q-FOR 28.2.21 Interim / Quarterly Report H1 2021	2021-04-14	English
FORM 10Q-FOR 28.2.21 Report Publication Announcement Q1 2021	2021-04-14	English
QUARTERLY REPORT Interim / Quarterly Report Q2 2021	2021-04-13	English
it has screened the first patient in its ORA-D-013-2 study second of two concurrent Phase 3 studies of its oral insulin capsule,ORMD-0801 Regulatory Filings	2021-03-23	English
it has screened the first patient in its ORA-D-013-2 study second of two concurrent Phase 3 studies of its oral insulin capsule,ORMD-0801 Regulatory Filings	2021-03-23	English
CURRENT REPORT Regulatory Filings	2021-03-23	English
entered into the definitive agreements with the formation of Oravax Medical Inc focused on the development of novel oral COVID-19 vaccines Regulatory Filings	2021-03-21	English
entered into the definitive agreements with the formation of Oravax Medical Inc focused on the development of novel oral COVID-19 vaccines Regulatory Filings	2021-03-21	English
CURRENT REPORT Regulatory Filings	2021-03-19	English
Reaches 25% Randomization in World’s First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol Earnings Release Q1 2021	2021-03-16	English
Reaches 25% Randomization in World’s First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol Report Publication Announcement	2021-03-16	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-03-03	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-03-03	English
Director's Dealing 2021 Director's Dealing	2021-03-02	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-02-18	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-02-18	English
Director's Dealing 2021 Director's Dealing	2021-02-17	English
Regulatory Filings 2021 Regulatory Filings	2021-02-11	English
AMENDMENT TO FORM SC 13G Major Shareholding Notification	2021-02-09	English
Regulatory Filings 2021 Regulatory Filings	2021-02-09	English
Regulatory Filings 2021 Regulatory Filings	2021-02-09	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-02-09	English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Director's Dealing	2021-02-09	English
Director's Dealing 2021 Director's Dealing	2021-02-08	English
Director's Dealing 2021 Director's Dealing	2021-02-08	English
Director's Dealing 2021 Director's Dealing	2021-02-08	English
Director's Dealing 2021 Director's Dealing	2021-02-08	English
Form 8K-clarifying that the Registration Statement on Form S-3 filed on February 3, 2021 was not in connection with a new primary issuance of shares Regulatory Filings	2021-02-05	English
Form 8K-clarifying that the Registration Statement on Form S-3 filed on February 3, 2021 was not in connection with a new primary issuance of shares Regulatory Filings	2021-02-05	English
CURRENT REPORT Regulatory Filings	2021-02-04	English
Form S-3 Regulatory Filings	2021-02-04	English
Form S-3 Report Publication Announcement	2021-02-04	English
REGISTRATION STATEMENT Registration Form	2021-02-03	English
Oramed Issues Letter to Shareholders Legal Proceedings Report	2021-01-28	English
Oramed Issues Letter to Shareholders Report Publication Announcement	2021-01-28	English
Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study Earnings Release Q1 2021	2021-01-21	English
Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study Report Publication Announcement	2021-01-21	English
FORM 10-Q-For the quarterly period ended November 30, 2020 Interim / Quarterly Report Q1 2021	2021-01-16	English
FORM 10-Q-For the quarterly period ended November 30, 2020 Report Publication Announcement Q1 2021	2021-01-16	English
QUARTERLY REPORT Interim / Quarterly Report Q1 2021	2021-01-14	English

Filings by year

2026 32 filings
2025 80 filings
2024 124 filings
2023 114 filings
2022 131 filings
2021 172 filings
2020 112 filings
2019 133 filings
2018 85 filings
2017 96 filings
2016 32 filings
2015 38 filings
2014 64 filings
2013 54 filings
2012 62 filings
2011 43 filings
2010 44 filings
2009 27 filings
2008 40 filings
2007 31 filings
2006 20 filings
2005 19 filings
2004 14 filings
2003 7 filings
2002 1 filing